Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. [electronic resource]
Producer: 20030128Description: 4310-6 p. digitalISSN:- 0006-4971
- Adult
- Aged
- Alemtuzumab
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized
- Antibodies, Neoplasm -- administration & dosage
- Antilymphocyte Serum
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Bone Marrow Transplantation
- Carmustine -- administration & dosage
- Cohort Studies
- Cytarabine -- administration & dosage
- Disease Progression
- Drug Resistance, Neoplasm
- Europe -- epidemiology
- Female
- Follow-Up Studies
- Graft Survival
- Graft vs Host Disease -- epidemiology
- Hodgkin Disease -- drug therapy
- Humans
- Immunosuppressive Agents -- therapeutic use
- Life Tables
- Lymphoma, Non-Hodgkin -- drug therapy
- Male
- Melphalan -- administration & dosage
- Middle Aged
- Peripheral Blood Stem Cell Transplantation -- adverse effects
- Podophyllotoxin -- administration & dosage
- Proportional Hazards Models
- Salvage Therapy
- Survival Analysis
- Survival Rate
- Transplantation Chimera
- Transplantation Conditioning
- Transplantation, Homologous -- adverse effects
- Treatment Outcome
- Vidarabine -- administration & dosage
No physical items for this record
Publication Type: Comparative Study; Journal Article; Multicenter Study
There are no comments on this title.
Log in to your account to post a comment.